Top

Mouhammed Amir Habra, M.D., F.A.C.P., F.A.C.E.

Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine

About Dr. Mouhammed Amir Habra

Dr. Mouhammed Amir Habra is an Assistant Professor at the University of Texas MD Anderson Cancer Center in Houston. A native of Syria, Dr. Habra graduated from faculty of Medicine, Aleppo University with honors and completed Internal Medicine residency training there. He pursued further training in internal medicine at the University of Missouri-Columbia where he also completed Internal Medicine training and then completed Endocrinology fellowship training at Baylor College of Medicine and The University of Texas MD Anderson Cancer Center. His fellowship training included advanced training focused on endocrine tumors and endocrine complications in cancer patients. Dr. Habra is board certified in both Internal Medicine and Endocrinology and recognized as a fellow of the American College of Physicians and The American College of Endocrinology. His major clinical and research interests are benign and malignant adrenal tumors, thyroid cancer, and Cushing syndrome. At MD Anderson, where he has been on faculty since 2008, Dr. Habra has provided both research based clinical care as well as patient care in traditional clinical setting.

Primary Appointment

Chief, Section of Endocrine Neoplasia, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX

Director, Thyroid Cancer Survivorship Clinic, Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texa

Research Interests

1. Clinical and molecular studies of benign and malignant adrenal tumors including adrenocortical carcinoma, adrenal adenomas, and pheochromocytoma

2. New treatments of endocrine malignancies including thyroid carcinoma and adrenocortical carcinoma

3. Novel markers and therapeutic targets in adrenal tumors

Education & Training

Degree-Granting Education

1995	Aleppo University, SY, MD

Postgraduate Training

2008-2011	Clinical Research Curriculum, Center for Clinical Research and Evidence-Based Medicine, University of Texas-Houston Medical School, Houston, Texas
2002-2005	Clinical Fellowship, Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, Houston, Texas
1999-2002	Clinical Residency, Internal Medicine, University of Missouri-Columbia, Columbia, Missouri
1995-1998	Clinical Residency, Internal Medicine, Aleppo University Hospital, Aleppo

Licenses & Certifications

2008	Texas State License
2004	American Board, Endocrinology, Diabetes and Metabolism
2002	American Board of Internal Medicine

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2020

Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2014

Staff Endocrinologist, Mid-Sussex Medical Center, Nanticoke Memorial Hospital, Seaford, DE, 2005 - 2008

Administrative Appointments/Responsibilities

Executive Chair, American Australian Asian Adrenal Alliance (A5), 2024 - 2026

Chief, Section of Endocrine Neoplasia, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present

Extramural Institutional Committee Activities

Member, Data Safety Monitoring Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2025

Member, Scientific Review Committee # 2, The University of Texas MD Anderson Cancer Center, 2021 - 2023

Member, Credentials Committee of the Medical Staff (CCMS), The University of Texas MD Anderson Cancer Center, 2013 - 2016

Member, Clinical Research Committee (CRC), The University of Texas MD Anderson Cancer Center, 2013 - 2021

Member, PRS Clinical Revenue Cycle Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2016

Member, Division of Medicine Research Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2016

Faculty Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2011 - 2014

Member, Survivorship Steering Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2013

Honors & Awards

2024	Top Performer, University of Texas MD Anderson Cancer Center
2023	Top Performer, University of Texas MD Anderson Cancer Center
2020	Top Performer, University of Texas MD Anderson Cancer Center
2019	Top Performer, The University of Texas MD Anderson Cancer Center
2017	Outstanding Teaching Award, Baylor College of Medicine/MD Anderson Fellowship Program
2014 - 2020	Top Doctor Award, Castle Connolly®

Professional Memberships

European Society of Endocrinology

2024 - Present

American Australian Asian Adrenal Alliance (A5)

2015 - Present

Syrian American Medical Society

2012 - Present

American Society of Clinical Oncology

2009 - Present

American Thyroid Association

2003 - Present

American Association of Clinical Endocrinologists

2002 - Present

Endocrine Society

2002 - Present

American College of Physicians

2001 - Present

Syrian Medical Syndicate

1995 - Present

Selected Presentations & Talks

Local Presentations

2025. Systemic Therapy in Adrenocortical Carcinoma. Invited. Oncologic Endocrine Lecture Series. Houston, Texas, US.
2025. The Management of Radioactive Iodine Refractory Differentiated Thyroid Carcinoma. Invited. Virtual. Houston, Texas, US.
2023. Clinical Management of Adrenocortical Carcinoma. Invited. Houston, Texas, US.
2023. Updates in the Evaluation and Management of Adrenal nodules. Invited. Houston, Texas, US.
2023. Adrenocortical Carcinoma: The latest preclinical and clinical updates. Invited. Endocrine Cancers and Adrenal Pituitary SIG Joint Webinar Presentation, Endocrine Society Webinar. Houston, Texas, US.
2021. Evaluation and Management of Adrenal Cortical Carcinoma,. Invited. American Association of Clinical Endocrinologists. Houston, Texas, US.
2021. Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2). Invited. ACC Summit; Virtual. Houston, Texas, US.
2020. Challenging Cushing Syndrome Cases. Invited. AACE Gulf Chapter Meeting; virtual. Houston, Texas, US.
2020. Approach to Suspicious Adrenal Masses. Invited. AACE Gulf Chapter Meeting; virtual. Houston, Texas, US.
2020. Primary Hyperaldosteronism: Uncertainties and Challenges,. Invited. AACE Gulf Chapter Meeting; virtual. Houston, Texas, US.
2019. Adrenal incidentaloma and adrenocortical carcinoma. Invited. Endocrine Fellows Education lecture. Houston, Texas, US.
2018. Current Management of Adrenocortical Carcinoma and Future Directions. Invited. 13th Update on the Management of Genitourinary Malignancies. Houston, Texas, US.
2018. Work-up of Adrenal Incidentalomas/Management of Adrenocortical Carcinoma. Invited. Department of Urology Didactic Conference. Houston, Texas, US.
2018. Managing Adverse Effects of Systemic Therapy-Thyroid Cancer. Eisai Preceptorship Course. Houston, Texas, US.
2018. Chemotherapy for Adrenocortical Carcinoma. Invited. Oncologic Endocrinology Lecture Series. Houston, Texas, US.
2018. Adrenal Masses: Endocrinology Perspective. Invited. 2018 Cancer Imaging and Intervention Conference. Houston, Texas, US.
2018. Adrenocortical carcinoma: updates and challenges. Invited. Endocrine Surgery Fellows Conference. Houston, Texas, US.
2018. Adrenocortical neoplasms: updates and uncertainties. Invited. Baylor College of Medicine, Endocrinology Grand Round. Houston, Texas, US.
2018. Adrenocortical neoplasms: updates and uncertainties. Invited. Adrenocortical neoplasms: updates and uncertainties. Houston, TX, US.
2017. Adrenocortical carcinoma: updates and challenges. Invited. Department of Endocrine Research Meeting. Houston, Texas, US.
2017. Adrenocortical neoplasms: updates. Invited. Department of Endocrine Neoplasia Research Meeting. Houston, Texas, US.
2017. Cushing Syndrome: Clinical Presentations and Etiologies. Invited. Endocrine Fellows Didactic Conference. Houston, Texas, US.
2017. Treatment of Advanced Adrenocortical Carcinoma. Invited. Oncologic Endocrinology Fellows conference. Houston, Texas, US.
2017. Perioperative Calcium Management. Invited. 7th Current Concepts in the Management of Thyroid and parathyroid neoplasms. Houston, Texas, US.
2016. Chemotherapy for Adrenocortical Carcinoma. Invited. Oncologic Endocrinology Fellows Conference. Houston, Texas, US.
2016. Chemotherapy in adrenocortical carcinoma. Invited. Oncologic Endocrinology Lecture Series 2016. Houston, Texas, US.
2016. Work up and management of adrenal incidentalomas and adrenocortical carcinoma. Invited. Department of Urology Didactic Conference. Houston, Texas, US.
2016. Work-up of incidental adrenal mass and management of adrenocortical carcinoma. Invited. Urology Didactic Conference. Houston, Texas, US.
2016. Evaluation and Management of the Incidental Adrenal Mass. Invited. 11th Urologic Oncology: Advances in Clinical Practice. Houston, Texas, US.
2016. Management of Adrenocortical Carcinoma. Advanced course on Surgical Oncology for The America's. Houston, Texas, US.
2015. Cushing Syndrome: Clinical Presentations and Etiologies. Invited. Endocrinology Fellows Conference. Houston, Texas, US.
2015. Cushing Syndrome: Clinical Presentations and Etiologies,. Invited. Endocrine Fellowship Didactic Conference. Houston, Texas, US.
2015. Systemic Therapy for Adrenocortical Carcinoma. Invited. 10th Urologic Oncology: Advances in Clinical Practice. Houston, Texas, US.
2015. Adrenocortical Carcinoma: 2015 Update. Invited. Endocrine Fellowship Didactic Conference. Houston, Texas, US.
2015. Adrenocortical Carcinoma 2015 Update. Invited. Endocrinology Fellows Conference. Houston, Texas, US.
2014. Adrenocortical Carcinoma: 2014 Update. Invited. Houston, Texas, US.
2014. Adrenocortical Carcinoma 2014 Update. Invited. Endocrinology Fellows Conference. Houston, Texas, US.
2014. Evidence based Case Discussion On Adrenocortical Carcinoma Management. Invited. 9th Urologic Oncology: Advances in Clinical Practice. Houston, Texas, US.
2013. Cushing Syndrome. Invited. Endocrinology Fellowship Curriculum Lecture. Houston, Texas, US.
2013. Adrenal Neoplasms in Cancer Center Setting. Invited. Internal Medicine and Cancer Survivorship Grand Rounds. Houston, Texas, US.
2013. Thyroid Carcinoma: Diagnosis and Management. Invited. Baylor College of Medicine, Medical Oncology. Houston, Texas, US.
2013. Thyroid Carcinoma: Diagnosis and Management. Invited. Thyroid Carcinoma: Diagnosis and Management. Houston, TX, US.
2012. Adrenal Incidentaloma and Adrenocortical Carcinoma. Invited. Endocrinology Fellowship Curriculum Lecture. Houston, Texas, US.
2012. Adrenocortical Carcinoma. Invited. Urology Department Didactic Conferenc. Houston, Texas, US.
2012. Cushing Syndrome. Invited. Endocrinology Fellowship Curriculum Lecture. Houston, Texas, US.
2011. Thyroid Cancer: Diagnosis and Staging, Christus St. John. Invited. Christus St. John. Nassau Bay, Texas, US.
2011. Adrenocortical Carcinoma. Invited. Baylor College of Medicine, Hematology and Oncolog. Houston, Texas, US.
2011. Adrenocortical Carcinoma. Invited. Adrenocortical Carcinoma. Houston, TX, US.
2011. Adrenal Incidentaloma and Adrenocortical Cancer. Invited. Endocrinology Fellowship Curriculum Lecture. Houston, Texas, US.
2010. Adrenal Incidentalomas. Invited. Urology Department Didactic Conference. Houston, Texas, US.
2010. Cushing Syndrome, Cushing Syndrome. Invited. Baylor College of Medicine, Endocrine. Houston, Texas, US.
2010. Adrenal Incidentaloma. Invited. Qatar Diabetes Endocrine and Metabolism Conference. Doha, QA.
2008. Adrenal Incidentalomas. Invited. Urology Department Didactic Conference. Houston, Texas, US.

Regional Presentations

2021. Adrenocortical Carcinoma: Approach and hurdles. Invited. University of Texas Southwestern, Endocrinology. Dallas, Texas, US.
2014. Can Cytopathology, Radiology and Molecular Markers Put Together the Pieces of the Adrenal Mass Puzzle?,. Invited. American Society of Cytopathology. Dallas, Texas, US.
2013. Endocrine Complications of Cancer Therapy. Invited. Christus St. John Hospital. Midland, Texas, US.
2013. Thyroid Cancer: 2013 Update. Invited. Midland Memorial Hospital. Midland, Texas, US.
2012. Thyroid Carcinoma: 2012 update. Invited. Citizens Medical Center, Oncology. Victoria, Texas, US.
2011. Evaluation and Management of Thyroid Nodules. Invited. Lubbock, Texas, US.
2010. The Thyroid Cancer Survivorship Clinic Model and Its Benefits for Patients. Invited. ThyCa: Thyroid Cancer Survivors' Association. Dallas, Texas, US.

National Presentations

2025. Adrenocortical Carcinoma:Current Status & Future Directions. Invited. University of Alabama-Birmingham (Virtual). Houston, Texas, US.
2024. A Practical Approach to Adrenal Neoplams: Knowledge Gaps and Current Guidelines. Invited. Department of Medicine Grand Rounds. Columbia, Missouri, US.
2024. Pushing Boundaries: New Strategies for Addressing Aggressive Adrenal Tumors: Approach to Advanced Adrenocortical Carcinoma (ACC). Invited. ENDO 2024, US.
2024. Pushing Boundaries: New Strategies for Addressing Aggressive Adrenal Tumors. Invited. Endocrine Society. Boston, MA, US.
2022. Adrenocortical Carcinoma: Approach and Management. Invited. City of Hope-Harbor-UCLA Medical Center, Endocrinology. Los Angeles, California, US.
2021. Clinical Approach to Adrenal Masses: Uncertainties and Challenges. Invited. East Carolina University, Endocrinology. Greenville, NC, US.
2021. Adrenocortical Carcinoma: Challenges and updates. Invited. University of California-San Diego, Endocrinology. San Diego, California, US.
2021. Adrenocortical Carcinoma: Approach and Management. Invited. New England Endocrine Fellows Didactic Series. Boston, MA, US.
2018. Evaluation and Management of Hypercalcemia. Invited. 10th Annual Tulane Thyroid and Parathyroid Symposium. New Orleans, Louisiana, US.
2018. Postoperative Surveillance of Thyroid Carcinoma. Invited. 10th Annual Tulane Thyroid and Parathyroid Symposium. New Orleans, Louisiana, US.
2018. Treating Malignant Pheochromocytoma in 2018. Invited. Endocrine Society Annual meeting. Chicago, MA, US.
2017. Recurrent Thyroid Cancer and RAI Challenging Case Presentations. Invited. 9th Annual Tulane Symposium on Thyroid and parathyroid Disease. New Orleans, Louisiana, US.
2017. Current ATA Guidelines for Postoperative RAI in Patients with Thyroid Cancer. Invited. 9th Annual Tulane Symposium on Thyroid and parathyroid Disease. New Orleans, Louisiana, US.
2017. Current Managment of Metastatic Thyroid Cancer. Invited. 9th Annual Tulane Symposium on Thyroid and parathyroid Disease. New Orleans, Louisiana, US.
2017. Postoperative Surveillance of Thyroid Cancer. Invited. 9th Annual Tulane Symposium on Thyroid and parathyroid Disease. New Orleans, Louisiana, US.
2017. Follicular Variant of Papillary Thyroid Carcinoma: Is it cancer or not?. Invited. 9th Annual Tulane Symposium on thyroid and parathyroid disease,. New Orleans, Louisiana, US.
2017. What's Different on the Current Guidelines for Workup of Thyroid Nodules. Invited. 9th Annual Tulane Symposium on thyroid and parathyroid disease. New Orleans, Louisiana, US.
2016. Case Management Forum Session: Adrenal Mass Evaluation and Management. Invited. Endocrine Society. Boston, MA, US.
2016. Master Clinician Session: Evaluation and Management of Adrenal Neoplasias. Invited. Endocrine Society. Boston, MA, US.
2015. Management of Hormonal Excess Syndromes in Adrenocortical Carcinoma. Invited. 5th International Adrenal Cancer Symposium. Ann Arbor, MI, US.
2014. Preexisting adrenal masses in patients with adrenocortical carcinoma: Beyond size alone. Invited. International Congress of Endocrinology/Endocrine Society Meeting. Chicago, Illinois, US.
2014. Adrenocortical Carcinoma: The role of Endocrinologists in Diagnosis and Management. Invited. American Association of Clinical Endocrinologists. Las Vegas, Nevada, US.
2013. Endocrine Complications of Cancer Therapy. Invited. Nassau Bay, TX, US.
2013. Thyroid Cancer: 2013 Update. Invited. Midland, TX, US.
2012. Keynote Lecture: Adrenocortical Carcinoma: Diagnostic and Therapeutic Challenges. Invited. Cleveland, OH, US.
2012. Thyroid Carcinoma: 2012 update. Invited. Citizens Medical Center. Victoria, TX, US.
2011. Thyroid Cancer: Diagnosis and Staging. Invited. Nassau Bay, TX, US.
2011. Clinical Management of Adrenocortical Carcinoma. Invited. The Endocrine Society 93rd Annual Meeting. Boston, MA, US.
2011. Evaluation and Management of Thyroid Nodules. Invited. Lubbock, TX, US.

International Presentations

2025. Bilateral Adrenal Masses: A case-based discussion. Invited. SAMS Endocrine Education Program (Virtual). Houston, US.
2025. Adrenal Incidentalomas: Case Studies. Invited. SAMS Endocrine Education Program (Virtual). Houston, US.
2025. Contemporary Approaches to Differentiated Thyroid Cancer: From Diagnosis to Long-Term Care. Invited. Aleppo University Hospital, SY.
2024. Approach to the Management of Advanced Adrenocortical Carcinoma (ACC). Invited. King Faisal Specialist Hospital & Research Centre, SA.
2021. Is immunotherapy a game changer?,. Invited. 8th International Adrenal cancer Symposium. Brescia, IT.
2020. Hormonal Management of Hypopituitarism. Invited. Qatar Diabetes Endocrine and Metabolism Conference; virtual. Houston, US.
2019. Adrenal Incidentalomas: Approach and Controversies. Invited. Toronto Adrenal Program. Toronto, CA.
2019. Primary hyperaldosteronism. Invited. Toronto Adrenal Program. Toronto, CA.
2019. Adjuvant therapy in high risk ACC ADIUVO-2 Trial. Invited. 7th International Adrenal Cancer Symposium. Clermont-Ferrand, FR.
2018. Adrenocortical Carcinoma. Invited. National Endocrine Congress. San Jose, CR.
2018. Hirsutism and Adrenal Neoplasms. Invited. National Endocrine Congress. San Jose, CR.
2018. Treatment of Radioactive iodine refractory differentiated thyroid carcinoma. Invited. National Endocrine Congress. San Jose, CR.
2018. Turning basic science into clinical research in adrenocortical carcinoma. Invited. The 18th Adrenal Cortex Conference. Munich, DE.
2018. New Developments on the Treatment of Radioiodine. Invited. 40 Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi, Antalya, TR.
2017. Perspectives: Immunotherapy for Adrenocortical Carcinoma. Invited. 6th International Symposium on Adrenocortical Carcinoma. Sao Paolo, BR.
2017. Adrenocortical neoplasms: Clinical approach and public health implications. Invited. 1st Vietnam Multidisciplinary Oncology Conference. Hanoi, VN.
2017. Current Management of Metastatic Thyroid Cancer. Invited. 1st Vietnam Multidisciplinary Oncology Conference. Hanoi, VN.
2015. Cushing Syndrome: Unusual Presentations and Etiologies. Invited. Egyptian Society of Endocrinology & Obesity. Alexandria, EG.
2015. The Management of Radioactive Iodine Refractory Differntiated Thyroid Carcinoma. Invited. 37th Turkey Endocrinology and Metabolism Diseases Congress. Antalya, TR.
2013. Adrenal Neoplasia: Case Presentations. Invited. 4th Joint Meeting American Association of Clinical Endocrinologist & Jordanian Society of Endocrinology and Metabolism. Amman, JO.
2013. Adrenocortical Carcinoma: Challenges and Hopes. Invited. 4th Joint Meeting American Association of Clinical Endocrinologist & Jordanian Society of Endocrinology and Metabolism. Amman, JO.
2013. Ectopic Cushing's Syndrome. Invited. 4th Joint Meeting American Association of Clinical Endocrinologist & Jordanian Society of Endocrinology and Metabolism. Amman, JO.
2013. Radiation Therapy in Adrenocortical Carcinoma: Local Treatment for Systemic Disease. Invited. Fourth International Symposium on Adrenal Cancer (FISAC. Paris, FR.
2012. Thyroid Carcinoma: 2012 Update. Invited. 12th annual International Convention-Syrian American Medical Society. Istanbl, TR.

Less

Grant & Contract Support

Date:	2018 - 2020
Title:	Smoking Related Oxidative Stress and Risk of Adrenocortical Carcinoma
Funding Source:	Institutional Research Grant, The University of Texas MD Anderson Cancer Center
Role:	PI
ID:	PA19-0296

Date:	2013 - 2019
Title:	Phase II Study of Cabozantinib in Patients with Radioiodine Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy, 2013-0220
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	2013-0220

Date:	2012 - 2017
Title:	Phase 2 Study of Pazopanib in Patients with Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma, 2012-0223
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	2012-0223

Date:	2012 - Present
Title:	Pharmacodynamic Study of Vemurafenib in the neoadjuvant setting in patients with locally advanced thyroid cancer, 2012-0471
Funding Source:	Genentech
Role:	Co-PI
ID:	2012-0471

Date:	2011 - 2018
Title:	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Funding Source:	Eisai
Role:	PI
ID:	2011-0035

Date:	2010 - 2011
Title:	Cryoablation use in Papillary Thyroid Cancer with Metastatic Cervical Lymphadenopathy: A pilot study 2010-0405
Funding Source:	Not Funded
Role:	PI
ID:	2010-0405

Title:	A Phase II Study to Evaluate the Effects of Cabozantinib in Patients with Unresectable/Metastatic Adrenocortical Carcinoma
Funding Source:	Exelixis
Role:	PI
ID:	2016-0741

Title:	Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers
Funding Source:	Radionetics Oncology
Role:	PI
ID:	2023-0178

Selected Publications

Peer-Reviewed Articles

Wolf KI, Osborne J, Lerario AM, Vo JN, Hamidi O, Habra MA, Hammer G, Else T. Adrenocortical Carcinoma as a Manifestation of Birt-Hogg Dube Syndrome. Endocr Relat Cancer, 2026. e-Pub 2026. PMID: 41838460.
Shariq OA, Kensing B, Landry JP, Tzeng CD, Habra MA, Campbell MT, Fisher SB, Perrier ND, Lee JE, Graham PH. Surgical management of metastatic adrenocortical carcinoma: Is there a role for multivisceral resection?. Surgery 189:109696, 2026. e-Pub 2026. PMID: 41006153.
Chahla, BB, Stephen, B, Song, J, Balderrama-Brondani, V, Yaylaci, F, Campbell, MT, Naing, A, Habra, MA. Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical Carcinoma. Journal of Immunotherapy and Precision Oncology 8(4):242-248, 2025. e-Pub 2025. PMID: 41143139.
Chan YS, Gao Q, Robinson SA, Wang W, Filandrova R, Weinhold LM, Cabrera ML, Zhang M, Ambati CSR, Lerario AM, Putluri N, Kiseljak-Vassiliades K, Wierman ME, Habra MA, Hammer GD, Veverka V, Cermakova K, Hodges HC. beta-catenin functions as a molecular adapter for disordered cBAF interactions. Mol Cell 85(16):3041-3056.e9, 2025. e-Pub 2025. PMID: 40695292.
Balderrama-Brondani V, Al-Ward R, Kiseljak-Vassiliades K, Fishbein L, Dawes D, Hamidi O, Pishdad R, Perdomo Rodriguez JP, Sukkari MA, Grajo JR, Ghayee HK, Bedrose S, Bassett RL, Hamrahian AH, Habra MA. Clinical and Radiological Features of Atypical Adrenal Masses-A Multicenter Retrospective Study. J Clin Endocrinol Metab 110(7):e2183-e2190, 2025. e-Pub 2025. PMID: 39503236.
Barat M, Eltaher M, Moawad AW, Soyer P, Fuentes D, Golse M, Jouinot A, Ahmed AA, Shehata MA, Assie G, Elmohr MM, Haissaguerre M, Habra MA, Hoeffel C, Elsayes KM, Bertherat J, Dohan A. A Computed Tomography-Based Score to Predict Survival in Patients With Adrenocortical Carcinoma: A Proof-of-Concept Study. Can Assoc Radiol J 76(4):8465371251335170, 2025. e-Pub 2025. PMID: 40319410.
Moussa, MJ, Wilson, NR, Ghosh, A, Bhattacharjee, M, Curry, JL, Cho, WC, Patel, A, Habra, MA, Thosani, S, Campbell, M, Siefker-Radtke, AO, Alhalabi, O, Kikani, NJ. Systemic Toxicity With Hyperglycemia or Diabetic Ketoacidosis After Enfortumab Vedotin. Annals of Internal Medicine Clinical Cases 4(5), 2025. e-Pub 2025.
Ma S, Wu L, Ye L, Habra MA, Balderrama-Brondani V, Wang W. Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma. Endocrine 88(2):597-606, 2025. e-Pub 2025. PMID: 39862362.
Szabo Yamashita, T, Tame-Elorduy, A, Skefos, CM, Varghese, J, Habra, MA, Fisher, SB, Graham, PH, Grubbs, EG, Waguespack, SG, Jimenez, C, Perrier, ND. SDHB-Associated Pheochromocytomas. Annals of surgical oncology 31(13):9007-9013, 2024. e-Pub 2024. PMID: 39382746.
Chahla, BB, Pal, K, Balderrama-Brondani, V, Yaylaci, F, Campbell, M, Sheth, RA, Habra, MA. Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma. Oncologist 29(10):850-858, 2024. e-Pub 2024. PMID: 38869364.
Laganà, M, Habra, MA, Remde, H, Almeida, MQ, Cosentini, D, Pusceddu, S, Grana, CM, Corssmit, EP, Bongiovanni, A, De Filpo, G, Lim, ES, Zamparini, M, Grisanti, S, Deutschbein, T, Fassnacht, M, Fagundes, GF, Pereira, MA, Oldani, S, Rota, S, Prinzi, N, Jimenez, C, Berruti, A. Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma. European Journal of Cancer 208, 2024. e-Pub 2024. PMID: 39047533.
Laganà, M, Brondani, VB, Herrera, KR, Chahla, BB, Yaylaci, F, Bassett Jr, R, Jimenez, C, Varghese, J, Waguespack, SG, Campbell, M, Shah, AY, Rojas Hernandez, CM, Habra, MA. Venous thromboembolism in adrenocortical carcinoma. Oncologist 29(7):575-580, 2024. e-Pub 2024. PMID: 38776552.
Jonasch, D, Habibollahi, P, Jones, AK, Avritscher, R, Habra, MA, Perrier, ND, Graham, PH, Huang, SY. Pre-procedural and intra-procedural computerized tomography. Abdominal Radiology 49(7):2401-2407, 2024. e-Pub 2024. PMID: 38740580.
Al-Ward, R, Brondani, VB, Sawani, S, Potter, CL, Xu, G, Waguespack, SG, Varghese, J, Habra, MA, Lu, Y, Jimenez, C. High-Specific-Activity 131I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clinical nuclear medicine 49(7):610-620, 2024. e-Pub 2024. PMID: 38630996.
Jimenez, C, Habra, MA, Campbell, M, Tamsen, G, Cruz-Goldberg, D, Long, JP, Bassett Jr, R, Dantzer, R, Brondani, VB, Varghese, J, Lu, Y. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial). The lancet oncology 25(5):658-667, 2024. e-Pub 2024. PMID: 38608693.
Campbell, M, Brondani, VB, Jimenez, C, Tamsen, G, Marcal, LP, Varghese, J, Shah, AY, Long, JP, Zhang, M, Ochieng, J, Haymaker, CL, Habra, MA. Cabozantinib monotherapy for advanced adrenocortical carcinoma. The lancet oncology 25(5):649-657, 2024. e-Pub 2024. PMID: 38608694.
Balderrama-Brondani, V, Griffin, AM, Owen, TJ, Merriman, K, Chahla, BB, Varghese, J, Jimenez, C, Waguespack, SG, Graham, PH, Perrier, ND, Fisher, SB, Karam, JA, Shah, AY, Campbell, M, Hassan, MM, Habra, MA. Incidence and Geographical Distribution of Adrenocortical Carcinoma. Endocrine Practice 30(1):25-30, 2024. e-Pub 2024. PMID: 37858722.
Sada, A, Foster, TR, Al-Ward, R, Sawani, S, Charchar, HE, Pishdad, R, Ben-Shlomo, A, Dy, BM, Lyden, ML, Bergsland, EK, Jasim, S, Raj, N, Shank, JB, Hamidi, O, Hamrahian, AH, Chambo, JL, Srougi, V, Fragoso, MC, Graham, PH, Habra, MA, Bancos, I, McKenzie, TJ. The effect of hormonal secretion on survival in adrenocortical carcinoma. Surgery (United States) 175(1):80-89, 2024. e-Pub 2024. PMID: 37945477.
Jimenez C, Ma J, Roman Gonzalez A, Varghese J, Zhang M, Perrier N, Habra MA, Graham P, Waguespack SG. TNM Staging and Overall Survival in Patients with Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 108(5):1132-1142, 2023. e-Pub 2023. PMID: 36433823.
Jimenez C, Chin BB, Noto RB, Dillon JS, Solnes L, Stambler N, DiPippo VA, Pryma DA. Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma. Endocr Relat Cancer 30(2), 2023. e-Pub 2023. PMID: 36472300.
Sarvestani AL, Gregory SN, Teke ME, Terzolo M, Berruti A, Hernandez JM, Habra MA. Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery. Ann Surg Oncol 30(2):680-682, 2023. e-Pub 2023. PMID: 36305989.
Shirali AS, Zagzag J, Chiang YJ, Huang H, Zhang M, Habra MA, Grubbs EG, Fisher SB, Perrier ND, Lee JE, Graham PH. Differences in Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas. Ann Surg Oncol 29(9):5555-5563, 2022. e-Pub 2022. PMID: 35499784.
Landry JP, Clemente-Gutierrez U, Pieterman CRC, Chiang YJ, Waguespack SG, Jimenez C, Habra MA, Halperin DM, Fisher SB, Graham PH, Perrier ND. Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery 172(2):559-566, 2022. e-Pub 2022. PMID: 35437162.
Murvelashvili N, Polanco PM, Khirsand SM, Marrero JA, Jia L, Mirfakhraee S, Else T, Habra MA, Cole S, Hamidi O. Severe Cholestatic Jaundice (Stauffer Syndrome) as a Rare Paraneoplastic Manifestation in Adrenocortical Carcinoma. Endocrine Society 6(8), 2022. e-Pub 2022. PMID: 35811575.
Srougi V, Habra MA, MCBV F. Response to Letter to the editor from Berruti et al.: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival.". J Clin Endocrinol Metab 107(7):E3101-E3102, 2022. e-Pub 2022. PMID: 35302610.
Srougi V, Habra MA, Villares Fragoso MCB. Response to Letter to the Editor From de Ponthaud et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival.". J Clin Endocrinol Metab 107(8):e3540, 2022. e-Pub 2022. PMID: 35188202.
Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients with Adrenocortical Carcinoma: A Multidisciplinary Referral Center Experience. J Clin Endocrinol Metab 107(5):1239-1246, 2022. e-Pub 2022. PMID: 35092681.
Shirali AS, Zagzag J, Chiang YJ, Huang H, Zhang M, Habra MA, Grubbs EG, Fisher SB, Perrier ND, Lee JE, Graham PH. ASO Visual Abstract: Differences in the Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas. Ann Surg Oncol. e-Pub 2022. PMID: 35552937.
Srougi V, Bancos I, Daher M, Lee JE, Graham PH, Karam JA, Henriquez A, Mckenzie T, Sada A, Bourdeau I, Poirier J, Vaidya A, Abbondanza T, Kiernan CM, Rao SN, Hamidi O, Sachithanandan N, Hoff AO, Chambo JL, Almeida MQ, Habra MA, MCBV F. Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival. J Clin Endocrinol Metab 107(4):964-971, 2022. e-Pub 2021. PMID: 34850915.
Jimenez C, Armaiz-Pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, Habra MA. Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. Cancers 14(3), 2022. e-Pub 2022.
Guccione J, Soliman M, Zhang M, Habra MA, Collins K, Zhao J, Elsayes KM. Imaging characteristics of pathologically proven adrenal adenomas with myelolipomatous degeneration: correlation with clinical and pathologic features. Br J Radiol 95(1129):20210555, 2022. e-Pub 2021. PMID: 34623887.
Qdaisat A, Bedrose S, Ezzeldin O, Moawad AW, Yeung SJ, Elsayes KM, Habra MA. The prevalence and spectrum of reported incidental adrenal abnormalities in abdominal computed tomography of cancer patients: The experience of a comprehensive cancer center. Front Endocrinol (Lausanne) 13:1023220, 2022. e-Pub 2022. PMID: 36457558.
Kimpel O, Bedrose S, Megerle F, Berruti A, Terzolo M, Kroiss M, Mai K, Dekkers OM, Habra MA, Fassnacht M. Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. Br J Cancer 125(9):1233-1238, 2021. e-Pub 2021. PMID: 34400803.
Moawad, AW, Ahmed, AA, Fuentes, DA, Hazle, JD, Habra, MA, Elsayes, KM. Machine learning-based texture analysis for differentiation of radiologically indeterminate small adrenal tumors on adrenal protocol CT scans. Abdominal Radiology 46(10):4853-4863, 2021. e-Pub 2021. PMID: 34085089.
Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, Dutcus CE, Xie R, Robinson B, Sherman SI, Habra MA, Elisei R, Wirth LJ. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio With Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated With Lenvatinib. Thyroid 31(8):1226-1234, 2021. e-Pub 2021. PMID: 33637020.
Collins K, Oramas DM, Guccione J, Elsayes KM, Habra MA, Zhang M, Cheng L. Incidentally discovered myelolipomatous adrenal adenomas, including six cases presenting with hypercortisolism. Pathol Res Pract 224:153508, 2021. e-Pub 2021. PMID: 34119816.
Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer 28(7):419-431, 2021. e-Pub 2021. PMID: 33890870.
Greenstein AE, Habra, MA, Wakekar SA, Grauer A. Adrenal tumors provide insight into the role of cortisol in NK cell activity. Society for Endocrinology 28(8):583-592, 2021. e-Pub 2021. PMID: 34086600.
Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, Pommier Y, Del Rivero J. The immunotherapy landscape in adrenocortical cancer. Cancers 13(11), 2021. e-Pub 2021.
Moawad AW, Ahmed A, Fuentes DT, Hazel JD, Habra MA, Elsayes KM. Machine learning-based texture analysis for differentiation of radiologically indeterminate small adrenal tumors on adrenal protocol CT scans. Abdominal Radiology, 2021. e-Pub 2021.
Daher M, Habra MA. Visual Vignette. Endocr Pract 26(12):1524, 2020. e-Pub 2020. PMID: 33471745.
Kiseljak-Vassiliades K, Bancos I, Hamrahian A, Habra MA, Vaidya A, Levine AC, Else T. American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: A practical approach. Endocrine Practice 26(11):1366-1383, 2020. e-Pub 2020.
Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel) 12(8), 2020. e-Pub 2020. PMID: 32824391.
Majidi F, Martino S, Kondakci M, Antke C, Haase M, Chortis V, Arlt W, Ronchi CL, Fassnacht M, Laurent C, Petit JM, Casanovas O, Habra MA, Kanji A, Salvatori R, Ho ATN, Spyroglou A, Beuschlein F, Villa D, Limvorapitak W, Wahlin BE, Gimm O, Rudelius M, Schott M, Germing U, Haas R, Gattermann N. Clinical Spectrum of Primary Adrenal Lymphoma: Results of a Multicenter Cohort Study. Eur J Endocrinol. e-Pub 2020. PMID: 32567556.
Daher M, Habra MA. HORMONALLY FUNCTIONING ECTOPIC ADRENOCORTICAL CARCINOMA. Endocr Pract. e-Pub 2020. PMID: 32339030.
Elsherif SB, Javadi S, Blair KJ, Morshid AI, Hui L, Khalaf AM, Elbanan MG, Zhang M, b|Habra MA, Elsayes KM. Preresection Radiologic Assessment and Imaging Features of 156 Pathologically Proven Adrenal Adenomas. J Comput Assist Tomogr. e-Pub 2020. PMID: 32345808.
Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. e-Pub 2020. PMID: 32437031.
Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32188704.
Ahmed AA, Elmohr MM, Fuentes D, Habra MA, Fisher SB, Perrier ND, Zhang M, Elsayes KM. Radiomic mapping model for prediction of Ki-67 expression in adrenocortical carcinoma. Clin Radiol. e-Pub 2020. PMID: 32089260.
Smith DC, Kroiss M, Kebebew E, Habra MA, Chugh R, Schneider BJ, Fassnacht M, Jafarinasabian P, Ijzerman MM, Lin VH, Mohideen P, Naing A. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest New Drugs. e-Pub 2020. PMID: 31984451.
Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, Lapa C, Quinkler M, Scherf-Clavel O, Habra MA, Fassnacht M. Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. J Clin Endocrinol Metab. e-Pub 2020. PMID: 31900481.
Economides MP, Shah AY, Jimenez C, Habra MA, Desai M, Campbell MT. A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Front Endocrinol (Lausanne) 11:594264, 2020. e-Pub 2020. PMID: 33329398.
Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7(1):253, 2019. e-Pub 2019. PMID: 31533818.
Fisher SB, Habra MA, Chiang YJ, Wu SY, Graham PH, Grubbs EG, Lee JE, Perrier ND. Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Manual for Adrenocortical Carcinoma. World J Surg. e-Pub 2019. PMID: 31493191.
Elmohr MM, Fuentes D, Habra MA, Bhosale PR, Qayyum AA, Gates E, Morshid AI, Hazle JD, Elsayes KM. Machine learning-based texture analysis for differentiation of large adrenal cortical tumours on CT. Clin Radiol. e-Pub 2019. PMID: 31362884.
Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM. Epidemiological Risk Factors for Adrenocortical Carcinoma: A Hospital-based Case-Control Study. Int J Cancer. e-Pub 2019. PMID: 31241762.
Berruti A, Libè R, Laganà M, Ettaieb H, Sukkari MA, Bertherat J, Feelders RA, Grisanti S, Cartry J, Mazziotti G, Sigala S, Baudin E, Haak H, Habra MA, Terzolo M. Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. Eur J Endocrinol 180(5):311-320, 2019. e-Pub 2019. PMID: 30970324.
Wannachalee T, Turcu AF, Bancos I, Habra MA, Avram AM, Chuang HH, Waguespack SG, Auchus RJ. The Clinical Impact of [68 Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone - Secreting Tumors. Clin Endocrinol (Oxf). e-Pub 2019. PMID: 31066920.
Thomas AJ, Habra MA, Bhosale PR, Qayyum AA, Ahmed K, Vicens R, Elsayes KM. Interobserver agreement in distinguishing large adrenal adenomas and adrenocortical carcinomas on computed tomography. Abdom Radiol (NY) 43(11):3101-3108, 2018. e-Pub 2018. PMID: 29671009.
Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6(1):68, 2018. e-Pub 2018. PMID: 29996921.
Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg 268(1):172-178, 2018. e-Pub 2018. PMID: 28257320.
Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer 124(11):2365-2372, 2018. e-Pub 2018. PMID: 29656442.
Romero Arenas MA, Whitsett TG, Aronova A, Henderson SA, LoBello J, Habra MA, Grubbs EG, Lee JE, Sircar K, Zarnegar R, Scognamiglio T, Fahey TJ, Perrier ND, Demeure MJ. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma. Ann Surg Oncol 25(3):801-807, 2018. e-Pub 2018. PMID: 29218429.
Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid 28(1):79-87, 2018. e-Pub 2018. PMID: 29161986.
Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-3599, 2017. e-Pub 2017. PMID: 28911154.
Mathiesen JS, Habra MA, Bassett JHD, Choudhury SM, Balasubramanian SP, Howlett TA, Robinson BG, Gimenez-Roqueplo AP, Castinetti F, Vestergaard P, Frank-Raue K. Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study. J Clin Endocrinol Metab 102(6):2069-2074, 2017. e-Pub 2017. PMID: 28323957.
Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer 75:213-221, 2017. e-Pub 2017. PMID: 28237867.
Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab:jc20162815. e-Pub 2016. PMID: 27662441.
Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol 78(1):167-71, 2016. e-Pub 2016. PMID: 27286994.
Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MC, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA, Research Network CGA, Hammer GD, Giordano TJ, Verhaak RG. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 29(5):723-36, 2016. e-Pub 2016. PMID: 27165744.
Altinmakas E, Guo M, Kundu UR, Habra MA, Ng C. Computed tomography and (18)F-fluorodeoxyglucose positron emission tomography/computed tomography findings in adrenal candidiasis and histoplasmosis: Two cases. Clin Imaging 39(6):1115-8, 2015. e-Pub 2015. PMID: 26298420.
Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres G, Sircar K, Wood CG, Hai T, Jimenez C, Cote GJ, Ozsari L, Hofmann MC, Zheng S, Verhaak R, Pagliaro L, Cortez MA, Lee MH, Yeung SC, Habra MA. Hepatocyte growth factor/cMET pathway activation enhances cancer hallmarks in adrenocortical carcinoma. Cancer Res 75(19):4131-42, 2015. e-Pub 2015. PMID: 26282167.
Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist 20(7):737-41, 2015. e-Pub 2015. PMID: 26054632.
Vodopivec DM, Habra MA, Ng C, Sircar K, Grubbs EG. Visual Vignette. Endocr Pract 21(7):854, 2015. e-Pub 2015. PMID: 26121444.
Dadu R, Hu MI, Cleeland CS, Busaidy N, Habra MA, Waguespack SG, Sherman SI, Ying AK, Fox P, Cabanillas M. The efficacy of the natural clay, Calcium Aluminosilicate Anti-Diarrheal (CASAD), in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: a pilot study. Thyroid. e-Pub 2015. PMID: 26200040.
Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. e-Pub 2015. PMID: 26206754.
Yogi-Morren D, Habra MA, Faiman C, Bena J, Hatipoglu B, Weil RJ, Hamrahian AH. Pituitary MRI Findings in Patients with Pituitary and Ectopic ACTH-Dependent Cushing Syndrome: Does A 6 MM Pituitary Tumor Size Cut-Off Value Exclude Ectopic ACTH Syndrome?. Endocr Pract. e-Pub 2015. PMID: 26121435.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621-30, 2015. e-Pub 2015. PMID: 25671254.
Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and Tolerability of Vemurafenib in Patients with BRAF(V600E) -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience. J Clin Endocrinol Metab 100(1):E77-81, 2015. e-Pub 2015. PMID: 25353071.
Phan L, Chou PC, Velazquez-Torres G, Samudio I, Parreno K, Huang Y, Tseng C, Vu T, Gully C, Su CH, Wang E, Chen J, Choi HH, Fuentes-Mattei E, Shin JH, Shiang C, Grabiner B, Blonska M, Skerl S, Shao Y, Cody D, Delacerda J, Kingsley C, Webb D, Carlock C, Zhou Z, Hsieh YC, Lee J, Elliott A, Ramirez M, Bankson J, Hazle J, Wang Y, Li L, Weng S, Rizk N, Wen YY, Lin X, Wang H, Wang H, Zhang A, Xia X, Wu Y, Habra MA, Yang W, Pusztai L, Yeung SC, Lee MH. The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming. Nat Commun 6:7530, 2015. e-Pub 2015. PMID: 26179207.
Wassal EY, Habra MA, Vicens R, Rao P, Elsayes KM. Ovarian thecal metaplasia of the adrenal gland in association with Beckwith-Wiedemann syndrome. World J Radiol 6(12):919-23, 2014. e-Pub 2014. PMID: 25550997.
Takeuchi S, Balachandran A, Habra MA, Phan AT, Jr BR, Macapinlac HA, Chuang HH. Impact of (18)F-FDG PET/CT on the management of adrenocorticol carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging 41(11):2066-73, 2014. e-Pub 2014. PMID: 24990404.
Falk NK, Weissferdt A, Habra MA, Roy-Chowdhuri S. Adrenocorticotropic hormone-producing thymic neuroendocrine carcinoma with oncocytic features: A case report and review of literature. Diagn Cytopathol. e-Pub 2014. PMID: 25354884.
Shawa H, Elsayes KM, Javadi S, Sircar K, Jimenez C, Habra MA. Clinical and radiologic features of pheochromocytoma/ganglioneuroma composite tumors: a case series with comparative analysis. Endocr Pract 20(9):864-9, 2014. e-Pub 2014. PMID: 24641930.
Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086-94, 2014. e-Pub 2014. PMID: 24628550.
Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz MH, Ng CS, Perrier ND, Lee JE, Grubbs EG. Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role For Preoperative Chemotherapy. World J Surg 38(6):1318-27, 2014. e-Pub 2014. PMID: 24615603.
Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients with Differentiated Thyroid Cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
Shawa H, Elsayes KM, Javadi S, Morani A, Williams MD, Lee JE, Waguespack SG, Busaidy NL, Vassilopoulou-Sellin R, Jimenez C, Habra MA. Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clin Endocrinol (Oxf) 80(3):342-7, 2014. e-Pub 2014. PMID: 24033606.
Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 169(6):891-899, 2013. e-Pub 2013. PMID: 24086089.
Morris LF, Harris RS, Milton DR, Waguespack SG, Habra MA, Jimenez C, Vassilopoulou-Sellin R, Lee JE, Perrier ND, Grubbs EG. Impact and timing of bilateral adrenalectomy for refractory adrenocorticotropic hormone-dependent Cushing’s syndrome. Surgery 154(6):1174-83; discussion 1183-4, 2013. e-Pub 2013. PMID: 24383115.
Shawa H, Deniz F, Bazerbashi H, Hernandez M, Sellin RV, Jimenez C, Habra MA. Mitotane Induced Hyperlipidemia: A Retrospective Cohort Study. International Journal of Endocrinology:624962, 2013. e-Pub 2013. PMID: 24348556.
Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C. The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2. J Clin Endocrinol Metab 98(11):E1813-9, 2013. e-Pub 2013. PMID: 24030942.
Ejaz S, Shawa H, Henderson SA, Habra MA. Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass. BMJ Case Rep 2013, 2013. e-Pub 2013. PMID: 23784764.
Cooper AB, Habra MA, Grubbs EG, Bednarski BK, Ying AK, Perrier ND, Lee JE, Aloia TA. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?. Surg Endosc. e-Pub 2013. PMID: 23765427.
Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C. Bone Metastases and Skeletal Related Events in Patients with Malignant Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 98(4):1492-7, 2013. e-Pub 2013. PMID: 23436918.
Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Metastatic Adrenocortical Carcinoma. Br J Cancer 108(4):826-30, 2013. e-Pub 2013. PMID: 23412108.
Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan A, Waguespack SG, Ayala-Ramirez M, Jimenez C, Perrier ND, Lee JE, Vassilopoulou-Sellin R. A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma. J Clin Endocrinol Metab 98(1):192-197, 2013. e-Pub 2013. PMID: 23150683.
Shawa H, Busaidy NL, Schellingerhout D, Habra MA. Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. BMJ Case Rep 2013, 2013. e-Pub 2013. PMID: 23682094.
Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97(11):4040-50, 2012. e-Pub 2012. PMID: 22965939.
Chuang HH, Deniz F, Sircar K, Jimenez C, Rubin De Celis C, Wood CG, Habra MA. [¹ F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case. J Clin Oncol 30(26):e246-9, 2012. e-Pub 2012. PMID: 22649135.
Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118(11):2804-12, 2012. e-Pub 2012. PMID: 22006217.
Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: The University of Texas MD Anderson Cancer Center Experience. Cancer 117(19):4381-9, 2011. e-Pub 2011. PMID: 21412758.
Khan MI, Habra MA, McCutcheon IE, Nogueras-González GM, Devin JK, Busaidy NL, Levine NB, Lindstrom W, Kagan D, Jimenez C, Waguespack SG. Random postoperative day-3 cortisol concentration as a predictor of hypothalamic-pituitary-adrenal axis integrity after transsphenoidal surgery. Endocr Pract 17(5):717-26, 2011. e-Pub 2011. PMID: 21454228.
Khan MI, Waguespack SG, Habra MA, Broaddus R, Jimenez C. Acute-Onset Ectopic Adrenocorticotropic Hormone Syndrome Secondary to Metastatic Endometrioid Carcinoma of the Ovaries As a Fatal Complication. J Clin Oncol 29(16):e462-4, 2011. e-Pub 2011. PMID: 21422435.
Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT Detecting Thyroid Plasmacytoma After the Successful Treatment of Gastric Large B-Cell Lymphoma. Clin Nucl Med 36(4):317-319, 2011. e-Pub 2011. PMID: 21368613.
Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators. J Clin Endocrinol Metab 96(3):717-25, 2011. e-Pub 2011. PMID: 21190975.
Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA. Multiple Endocrine Neoplasia Type 2B with a RET Proto-Oncogene A883F Mutation Displays a More Indolent Form of Medullary Thyroid Carcinoma Compared With a RET M918T Mutation. Thyroid 21(2):189-192, 2011. e-Pub 2011. PMID: 21186952.
Ayala-Ramirez M, Habra MA, Busaidy N, Cote G, Rich T, Waguespack S, Jimenez C. A catecholamine crisis on Mount Kilimanjaro: a hypoxia effect?. J Travel Med 17(6):424-6, 2010. e-Pub 2010. PMID: 21050326.
Habra MA, Núñez R, Chuang H, Ayala-Ramirez M, Rich T, Kyle K, Jimenez C. Fatal hypoglycemia in malignant pheochromocytoma: direct glucose consumption as suggested by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging. Endocrine 37(1):209-212, 2010. e-Pub 2010. PMID: 20963572.
Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA, Gagel RF, Hoff AO. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 14(9):1108-14, 2008. e-Pub 2008. PMID: 19158050.
Habra MA, Weaver EJ, Prewitt PV. Primary cutaneous large B-cell lymphoma of the leg and acute hypercalcemia. J Clin Oncol 25(36):5825-6, 2007. e-Pub 2007. PMID: 18089880.
Thompson MA, Habra MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG, Rodriguez MA. Primary adrenal natural killer/T-cell nasal type lymphoma: first case report in adults. Am J Hematol 82(4):299-303, 2007. e-Pub 2007. PMID: 17094095.
Habra MA, Vassilopoulou-Sellin R. Contribution of routine chest x-ray in the long-term follow-up of patients with differentiated thyroid carcinoma. Thyroid 16(3):303-6, 2006. e-Pub 2006. PMID: 16571094.
Habra MA, Jimenez C, Wallace M, Evans, DB, Vassilopoulou-Sellin R. Insulinoma in a Marathon Runner Illustrating the Effects of Exercise on Insulin Sensitivity and Glucose Homeostasis. The Endocrinologist 16(1):20-24, 2006. e-Pub 2006.
Picolos MK, Habra M, Safdar A, Sarlis NJ. Inactive pulmonary tuberculosis mimicking metastasis from papillary thyroid carcinoma in diagnostic radioiodine whole-body scintigraphy. Thyroid 15(9):1105-6, 2005. e-Pub 2005. PMID: 16187924.
Habra MA, Feig BW, Waguespack SG. Image in endocrinology: adrenal pseudocyst. J Clin Endocrinol Metab 90(5):3067-8, 2005. e-Pub 2005. PMID: 15872337.
Habra MA, Vassilopoulou-Sellin R. Cervical spine metastasis mimicking thyroid bed uptake in follicular thyroid carcinoma. Thyroid 15(3):298-9, 2005. e-Pub 2005. PMID: 15785252.
Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716-26, 2004. e-Pub 2004. PMID: 15287039.
Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF. Pheochromocytoma and Medullary Thyroid Carcinoma: A New Genotype-Phenotype Correlation of the RET Protooncogene 891 Germline Mutation. J Clin Endocrinol Metab 89(8):4142-5, 2004. e-Pub 2004. PMID: 15292360.

Invited Articles

Jasim S, Habra MA. Management of Adrenocortical Carcinoma. Curr Oncol Rep 21(3):20, 2019. e-Pub 2019. PMID: 30798468.
Michelle M A, Jensen CT, Habra MA, Menias CO, Shaaban AM, Wagner-Bartak NA, Roman-Colon AM, Elsayes KM. Adrenal cortical hyperplasia: diagnostic workup, subtypes, imaging features and mimics. Br J Radiol 90(1079):20170330, 2017. e-Pub 2017. PMID: 28707538.
Wagner-Bartak NA, Baiomy A, Habra MA, Mukhi SV, Morani AC, Korivi BR, Waguespack SG, Elsayes KM. Cushing Syndrome: Diagnostic Workup and Imaging Features, With Clinical and Pathologic Correlation. AJR Am J Roentgenol 209(1):19-32, 2017. e-Pub 2017. PMID: 28639924.
Varghese J, Habra MA. Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes 24(3):208-214, 2017. e-Pub 2017. PMID: 28277340.
Rao SN, Habra MA. 5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications. Horm Cancer 7(1):17-23, 2016. e-Pub 2016. PMID: 26660146.
Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev 42:47-55, 2016. e-Pub 2016. PMID: 26678514.
Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arti-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171(3):R111-22, 2014. e-Pub 2014. PMID: 24891137.
Jasim S, Ozsari L, Habra MA. Multikinase inhibitors use in differentiated thyroid carcinoma. Biologics 8:281-91, 2014. e-Pub 2014. PMID: 25506209.
Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, Baudin E. Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma. Curr Oncol Rep. e-Pub 2013. PMID: 23674235.
Yeung SC, Habra MA, Thosani SN. Lung cancer-induced paraneoplastic syndromes. Curr Opin Pulm Med 17(4):260-8, 2011. e-Pub 2011. PMID: 21577115.
Santarpia L, Habra MA, Jiménez C. Malignant Pheochromocytomas and Paragangliomas: Molecular Signaling Pathways and Emerging Therapies. Horm Metab Res 41(9):680-6, 2009. e-Pub 2009. PMID: 19343618.
Habra M, Sarlis NJ. Thyroid and aging. Rev Endocr Metab Disord 6(2):145-54, 2005. e-Pub 2005. PMID: 15843886.

Review Articles

Jimenez C, Armaiz-Pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, Habra MA. Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. Cancers (Basel) 14(3), 2022. e-Pub 2022. PMID: 35158739.
Pegna, GJ, Roper, N, Kaplan, RN, Bergsland, EK, Kiseljak-Vassiliades, K, Habra, MA, Pommier, Y, Del Rivero, J. The immunotherapy landscape in adrenocortical cancer. Cancers 13(11), 2021. e-Pub 2021. PMID: 34071333.
Mazzaglia PJ, Varghese J, Habra MA. Evaluation and management of adrenal neoplasms: endocrinologist and endocrine surgeon perspectives. Abdom Radiol (NY). e-Pub 2020. PMID: 32189021.
Bedrose S, Daher M, Altameemi L, Habra MA. Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions. Cancers (Basel) 12(2), 2020. e-Pub 2020. PMID: 32098326.
Ahmed AA, Thomas AJ, Ganeshan DM, Blair KJ, Lall C, Lee JT, Morshid AI, Habra MA, Elsayes KM. Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management. Abdom Radiol (NY). e-Pub 2020. PMID: 31894378.
Elbanan MG, Javadi S, Ganeshan D, Habra MA, Rao Korivi B, Faria SC, Elsayes KM. Adrenal cortical adenoma: current update, imaging features, atypical findings, and mimics. Abdom Radiol (NY). e-Pub 2019. PMID: 31529204.
Morani AC, Jensen CT, Habra MA, Agrons MM, Menias CO, Wagner-Bartak NA, Shaaban AM, Roman-Colon AM, Elsayes KM. Adrenocortical hyperplasia: a review of clinical presentation and imaging. Abdom Radiol (NY). e-Pub 2019. PMID: 31093730.
Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2013. PMID: 23185034.
Habra MA, Hijazi R, Verstovsek G, Marcelli M. Medullary thyroid carcinoma associated with hyperthyroidism: a case report and review of the literature. Thyroid 14(5):391-6, 2004. e-Pub 2004. PMID: 15186618.

Professional Educational Materials

Yeung SC, Habra MA. Atlas of Genetics and Cytogenetics in Oncology and Haematology-Anaplastic Thyroid Carcinoma, 2012.
Yeung SC, Habra MA. Atlas of Genetics and Cytogenetics in Oncology and Haematology-parathyroid hormone-like protein (PTHLP), 2012.

Editorials

Hajjar J, Habra MA, Naing A. Metformin: An Old Drug with New Potential. Expert Opinion on Investigational Drugs 22(12):1511-1517, 2013. PMID: 23978196.

Abstracts

Zheng L, Balderrama-Brondani V, Habra MA, Zhang M. Intercellular adhesion molecule-1 (ICAM-1) expression in adrenal cortical carcinomas. United States and Canadian Academy of Pathology’s 113th Annual Meeting, 2024. e-Pub 2024.
Yamashita TS, Skefos CM, Varghese J, Habra MA, Fisher SB, Graham PH, Grubbs EG, Waguespack SG, Jimenez C, Perrier ND. SDHB-associated Pheochromocytomas: What is their clinical behavior?. Society of Surgical Oncology, 2024. e-Pub 2024.
Pal K, Chahla B, Balderrama-Brondani V, Cambpell MT, Habra MA, Sheth. Clinical Outcomes of Imaging-Guided Localized Treatments in Patients with Adrenocortical Carcinoma: A Retrospective Study. Society of Interventional Radiology, 2024. e-Pub 2024.
Jimenez C, Habra MA, Tamsen G, Cambpell MT, Long JP, Bassette RL, Balderrama-Brondani V, Potter CL, Cruz-Goldberg D, Garza JA, Lu Y. A phase 2 clinical trial of cabozantinib in patients with unresectable and progressive metastatic pheochromocytoma or paraganglioma: The NATALIE trial". North American Neuroendocrine Tumor Society, 2023. e-Pub 2023.
Yamashita TS, Avula KA, Podrat JL, Lee-Kim S, Chiang Y, Williams LA, Zafereo ME, Graham PH, Perrier ND, Habra MA, Grubbs EG, Fisher SB. Patient Reported Outcomes: What symptoms do long term thyroid cancer survivors experience?. American Thyroid Association, 2023. e-Pub 2023.
Yamashita TS, Al-Ward R, Xu G, Lu Y, Fisher SB, Grubbs EG, Perrier ND, Waguespack SG, Varghese J, Habra MA, Jimenez C, Graham PH. Does disease debulking of metastatic Pheochromocytoma and Paranganglioma alter treatment with High-specific-activity Iodine 131 Metaiodobenzylguanidine?. Society of Nuclear Medicine & Molecular Imaging, 2023. e-Pub 2023.
Balderrama-Brondani V, Griffin AM, Owen TJ, Merriman KW, Varghese J, Jimenez C, Waguespack SG, Graham PH, Campbell C, Hassan M, Habra MA. Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocrine Society, 2023. e-Pub 2023.
Sada A, Foster TR, Al-Ward R, Charchar H, Pishdad R, Dy BM, Lyden ML, Bergsland E, Jasim S, Raj N, Shank JB, Hamidi O, Hamrahian AH, Chambo JL< Srougi V, MCBV F, Graham PH, Habra MA, Bancos I, McKenzie TJ. The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study. American Association of Endocrine Surgery, 2023. e-Pub 2023. PMID: 37945477.
Campbell, MT, Jimenez C, Long JP, Varghese J, Shah AY, Zhang M, Tamsen G, Habra MA. An Open-Label Phase II Trial of Cabozantinib for Advanced Adrenocortical Carcinoma. European Society of Medical Oncology, 2022. e-Pub 2022.
Kiseljak-Vassiliades K, Kar A, Pozdeyev N, Foust L, Bagby S, Pitts T, Habra MA, Wierman M. Comprehensive profiling of the MELK inhibitor OTSSP167's action and its effect on sensitization to Wee1 inhibitor AZD1775 in a spectrum of ACC models. Endocrine Society, 2022. e-Pub 2022.
Al-Ward R, Sawani S, Bassett R, Xu G, Waguspack SG, Varghese J, Lu Y, Balderrama Borndani V, Habra MA, Jimenez C. High-specific-activity Iodine 131 Metaiodobenzylguanidine For The Treatment Of Advanced Pheochromocytoma And Paraganglioma: A Real-world Study. Endocrine Society, 2022. e-Pub 2022.
Collins K, Cheng L, Oramas-Mogrvejo DM, Guccione J, Elsayes KM, Habra MA, Zhang M. Myelolipomatous Adrenal Adenomas: A Report of 15 Cases. College of American Pathologists, 2021. e-Pub 2021.
Greenstein AE, Habra MA, Mura M, Biernat P, Piatek MJ, Grauer A, Shepherd SP. Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid. American Association for Cancer Research (AACR), 2020. e-Pub 2020.
Bedrose SSD, Altameemi L, Daher M, Tamsen de Rosa G, Varghese JM, Jimenez C, Campbell M, MA &. Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma. ENDO 2020, 2020. e-Pub 2020.
Faazeli S, Dadu R, Waguespack SG, Sherman SI, Busaidy L, Hu MI, Jimenez C, Habra MA, Williams M, Altameemi L, Poropatich K, Routbort MJ, Luthra R, Patel KP, Cabanillas M. TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center. ENDO 2020, 2020. e-Pub 2020.
Majidi F, Martino S, Kondakci M, Haase M, Chortis V, Arlt W, Ronchi CL, Fassnacht M, Laurent C, J-M P, Casasnovas O, Habra MA, Kanji A, Salvatori R, Ho A, Spyroglou A, Beuschlein F, Villa D, Limvorapitak W, Wahlin B, Gimm O, Rudelius M, Schott M, Germing U, Haas R, Gattermann N. Isolated Primary Adrenal Lymphoma-An Emerging Lymphoma Entity? Results of a retrospective Multicenter Study. Congress of the European Hematology Association, 2019. e-Pub 2019.
Taylor MH, Tahara M, Wirth LJ, Robinson B, Habra MA, Kiyota N, Lee EK, Misir S, Joshi P, Ren N, Elisei R, De La Fouchardiere C, Leboulleux S, Sherman SI, Takahashi S. Lenvatinib in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in SELECT: Post hoc analysis of neutrophil-to-lymphocyte ratio (NLR). American Society of Clinical Oncology, 2019. e-Pub 2019.
Thosani S, Best C, Lavis V, Habra MA, Busaidy N, Varghese J, Hu M, Cabanillas M, Dadu R, Gagel R, Waguespack S, Weitzman SP, Jimenez C. Improving Documentation for Hypoglycemia Treatment in Hospitalized Patients at MD Anderson Cancer Center. 2019 Internal Medicine Research Retreat University of Texas MD Anderson Cancer Center, 2019. e-Pub 2019.
Hu MI, Cote CJ, Hai T, Busaidy NL, Cabanillas ME, Dadu R Gagel RF, Grubbs EG, Habra MA, Jimenez C, Subbiah V, Waguespack SG, Williams MD, Zafereo S, Sherman SI. Emergence of Resistance-Associated Mutations of RET V804M and KRAS in Medullary Thyroid Carcinoma (MTC) Patients Treated with Tyrosine Kinase Inhibitors (TKI) Cabozantinib and Vandetanib. ATA Spring Satellite Symposium 2019: Diagnostic Imaging and Image-Guided Therapies for Thyroid Disease, 2019. e-Pub 2019.
Kojima Y, Sircar K, Habra MA, Zhang M. Biomarker profiles in Adrenal Cortical Carcinomas. USCAPS, 2019. e-Pub 2019.
Dadu R, Cabanillas ME, de Groot P, Chang JY, Tang C, Sherman SI, Busaidy N, Waguespack SG, Hu MI, Ying A, Habra MA, Menon H, Welsh J. Ipilimumab with stereotactic ablative radiation therapy (SABR): Results of a thyroid cancer expansion cohort. American Thyroid Association 87th Annual Meeting, 2018. e-Pub 2018.
MT, Lemke E, Elsayes KM, Bazerbashi B, Shah AY, Habra MA. A retrospective analysis of carboplatin plus etoposide in patients with adrenal cortical carcinoma. ASCO Annual Meeting. e-Pub 2018.
Thomas A, Habra MA, Qayyum A, Bhosale P, Vicens R, Elsayes K. Distinguishing large adrenal adenomas and adrenocortical carcinomas: Findings on. American Roentgen Ray Society Annual Meeting. e-Pub 2018.
Wendler J, Habra MA, Ronchi CL, Megerle F, Schreiner J, Lapa C, Fassnacht M, Matthias Kroiss M. Objective Response to Cabozantinib in Refractory Adrenocortical Carcinoma: A Case Series. Endocrine Society 2018 meeting, 2018. e-Pub 2018.
Nguyen H, Shah K, Waguespack SG, Habra MA, Hu MI, Iyer P, Kaya, Pitteloud MJ, Subudhi SK, Diab A, Dadu R. Immune-related Hypophysitis (irh) Associated With Checkpoint Inhibitor Therapy: Diagnosis, Characteristics And Long Term Follow Up. Endocrine Society 2018 meeting:SUN-592, 2018. e-Pub 2018.
Majidi F, Marino S, Haase M, Chortis V, Arlt W, Ronchi CL, Fassnacht M, Laurent C, Casanovas O, Petit JM, Habra MA, Kanji A, Salvatori R, Ho ATN, Spyroglou A, Beuschlein F, Rudelius M, Schott M, Germing U, Has R, Gattermann N. Multicenter Case Series of Primary Adrenal Lymphoma (PAL). 59th Annual meeting of the American Society of Hematology. e-Pub 2017.
Habra MA, Campbell M, Jimenez C, Karp D, Hong D, Subbiah V, Pant S, Painter J, Khan S, Berntachez C, Stephen B, Alshawa A, Tapia C, Mendoza T, Colen R, Hess K, Meric-Berntam F, Naing A. Efficacy of Pembrolizumab (MK-3475) in Patients with Adrenocortical Carcinoma. SITC 32nd Annual Meeting. e-Pub 2017.
Elsayes KM, Morshid A, Duran E, Zhang M, Habra MA. Adrenocortical Carcinoma: Pathology, Imaging Workup, Typical/atypical features, pitfalls and mimics. Does Ki-67 correlate with imaging features. RSNA 2017. e-Pub 2017.
Iyer P, Ferrarotto R, Gule-Monroe M, Busaidy N, Dadu R, Habra MA, Williams MD, Hofmann M, Zafereo M, Skinner H, Cabanillas ME. Emergence of V804M resistance gatekeeper mutation in sporadic medullary thyroid carcinoma patients treated with TKI tyrosine kinase inhibitors. American Thyroid Association 87th Annual Meeting. e-Pub 2017.
Habra MA, Song J, Rietschel P. Outcomes by Site of Metastasis for Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib Versus Placebo: Results from a Phase 3, Randomized Trial. 15th International Thyroid Congress. e-Pub 2015.
Brose MS, Teng A, Rietschel P, Habra MA. Lenvatinib and the Effect of Age on Overall Survival for Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. 15th International Thyroid Congress. e-Pub 2015.
Clifton GT, Habra MA, Aloia TA, Vauthey JN, Evans DB, Perrier ND, Grubbs EG, Lee JE. Effective surgical treatment of adrenal cortical carcinoma may not require routine regional lymphadenectomy. American Association of Endocrine Surgeons, 2015. e-Pub 2015.
Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Dutcus C, Xu J, Zhu J, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Pharmacodynamic biomarkers of outcomes in the phase 3 study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). American Society of Clinical Oncology, 2015. e-Pub 2015.
Romero Arenas MA, Whitsett TG, Aronova A, Henderson S, LoBello J, Habra MA, Grubbs EG, Lee JE, Sirkar K, Zarnegar R, Scognamiglio T, Fahey T, Perrier ND, Demeure MJ. Protein expression of PTTG1 as a diagnostic biomarker in Adrenocortical Carcinoma. American Association of Endocrine Surgeons, 2015. e-Pub 2015.
Kwatampora L, Clarke C, Silva A, Zorba Y, Williams MD, Broaddus R, Clayman GL, El-Naggar AK, Gagel RF, Grubbs EG, Habra MA, Hu MI, Jimenez C, Kopetz S, Lee JE, Sherman SI, Vassilopoulou-Sellin R, Waguespack S, Perrier ND, Busaidy NL. Recurrent parathyroid carcinoma—a need for molecular profiling to aid in prognostication and therapeutics. American Society of Clinical Oncology, 2015. e-Pub 2015.
Yu W, Habra MA, Raghu V, Katz R. Utility of Immunohistochemical Expression of Ki-67, Beta-Catenin, P53 and AR in Assessment of Primary Adrenal Cortical Neoplasms. United States adn Canadian Academy of Pathology, 2015. e-Pub 2015.
Ozsari L, Phan L, Fuentes-Mattei E, Velazquez-torres G, Sircar K, Jimeenz C, Cote G, M-C H, M-H L, Yeung S-C J, Habra MA. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma: A Potential Therapeutic Target. Endocrine Society, 2015. e-Pub 2015.
Jasim S, Kwatampora LJ, Elsayes K, Tamboli P, Busaidy NL Habra MA. Epithelioid Angiomyolipoma Mimicking Adrenocortical Carcinoma in a Patient with Li-Fraumeni Syndrome. Endocrine Society, 2015. e-Pub 2015.
Pitteloud MJ, Dadu R, Cabanillas ME, Shah K, Hu MI, Habra MA, Waguespack SG. Hypophysitis in the Age of Cancer Immunotherapy: Experience in a Large Cancer Center. Endocrine Society, 2015. e-Pub 2015.
Roman-Gonzalez A, Jimenez C, Habra MA. Sporadic Medullary Thyroid Carcinoma with Symptomatic Pituitary Metastasis During Vandetinib. 15th International Thyroid Congress. e-Pub 2015.
Habra MA, Schluberger M, Wirth L, Robinson B, Brose MS, Taylor MH, Gianoukakis AG, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI, Shah MH. Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (Select): Results and Subgroup Analysis of Patients from North America. American Thyroid Association 84th Annual Meeting. e-Pub 2014.
Dadu R, Hu MI, Cleeland CS, Busaidy NL, Habra MA, Waguespack SG, Sherman SI, Ying AK, Fox P, Cabanillas M. The Efficacy of the Natural Clay, CASAD, in Reducing Medullary Thyroid Cancer (MTC)-Related Diarrhea and its Effects on Quality of Life (QOL): A Pilot Study. American Thyroid Association 84th Annual Meeting. e-Pub 2014.
Mallesara SS, Hu MI, Kontoyiannis D, Williams MD, Ying AK, Habra MA. Mucormycosis Thyroiditis- A Rare Cause of Thyroiditis and Hyperthyroidism in Patients with Hematological Malignancies. American Thyroid Association 84th Annual Meeting. e-Pub 2014.
Schlumberger M, Tahara M, Wirth L, Robinson B, Brose M, Elisei R, Dutcus C, de las Heras B, Zhu J, Habra MA, Newbold K, Shah M, Hoff AO, Gianoukakis AG, Kiyota N, Taylor M, S-B K, Krzyzanowska M, Sherman SI. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). ASCO Annual Meeting 2014, 2014. e-Pub 2014.
Busaidy NL, Habra MA. Metastatic Parathyroid Carcinoma and Hypercalcemia Responds to Treatment with Sorafenib. International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014:14952, 2014. e-Pub 2014.
Kutahyalioglu M, Elsayes K, Vicens RA, Sircar K, Jazaerly T, Ozsari L, Jimenez C, Waguespack SG, Busaidy NL, Cabanillas ME, Grubbs EG, Habra MA. Preexisting Adrenal Masses in patients with Adrenocortical Carcinoma: Byeond Size Alone. International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014, 2014. e-Pub 2014.
Naing A, Habra MA, Chugh R, Ijezrman M, Hesseltine E, Worden F, Phillips M, Smith D. Phase 1 study of ATR-101 in adrenocortical carcinoma (ACC): ATR-101-001. ASCO Annual Meeting 2014, 2014. e-Pub 2014.
Fuentes-Mattei E, Phan L, Velazquez-Torres G, Wu W, SIrcar K, Wood CG, Hai T, Jimenez C, Cote G, Lee MH, Yeung SC J, Habra MA. Inhibition of HGF/cMet signaling as a therapeutic approach for adrenocortical cancer tumor progression and drug resistance. MDACC Divisoin of Medicine Research Retereat 2014, 2014. e-Pub 2014.
Phan L, Feuntes-Mattei E, Velazquez-Torres G, Wu W, Sircar K, Wood CG, Hai T, Jiemenz C, Cote G, Lee MH, Yeung SC J, Habra MA. Hepatocyte Growth Factor and c-Met Signaling Promotes Growth of Adrenocortical Carcinoma. MDACC Divison of Medicine Research Reterat 2014, 2014. e-Pub 2014.
Dadu R, Shah K, Waguespack SG, Sherman SI, Habra MA, Busaidy N, Jimenez C, Ying A, Hu MI, Cabaniallas ME. Efficacy and tolerability of vemurafenib in BRAFV600E positive papillary thyroid cancer (PTC). The American Thyroid Association 83rd meeting, 2013. e-Pub 2013.
Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack SG, Hu MI, Ying A, Habra MA, Jimenez C, Sellin RV, Cote G, Sherman SI, Cabanillas ME. Survival and Efficacy of Salvage Tyrosine Kinase Inhibitors (TKIs) after First Line Sorafenib (SOR) Failure in Patients with Advanced Differentiated Thyroid Cancer (DTC). The American Thyroid Association 83rd meeting, 2013. e-Pub 2013.
Bendarski BK, Habra MA, Phan A, Evans DB, Katz MH, Perrier ND, Grubbs EG, Lee JE. Borderline resectable adrenocortical carcinoma: a potential role for preoperative chemotherapy. International Surgical Week: Helskinki, Finland, 2013. e-Pub 2013.
Yogi-Morren D, Habra MA, Faiman C, Hatipoglu BA, Kennedy L, Weill RJ, Hamrahian AH. Pituitary adenoams in ectopic Cushing syndrome. Endocrine Society 95th meeting, 2013. e-Pub 2013.
Dadu R, Busaidy N, Hernandez M, Devine CE, Steven Waguespack SG, Habra MA, Hu M, Ying A, Cabanillas ME. Overall survival (OS) in patients with differentiated thyroid carcinoma (DTC) receiving salvage targeted therapy after first line sorafenib (sor) failure. Endocrine Society 95th meeting, 2013. e-Pub 2013.
Deniz F, Bazerbashi H, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Mitotane induced HDL-cholesterol elevation: A retrospective cohort study. Endocrine Society 95th meeting, 2013. e-Pub 2013.
Takeuchi S, Balachandran A, Habra MA, Phan A, Macapinlac HA, Chuang H. The usefulness of 18F-FDG PET for the management of adrenocortical carcinoma. Society of Nuclear Medicine and Molecular Imaging:1628487, 2013. e-Pub 2013.
Cooper A, Habra MA, Grubbs EA, Bendarski B, Ying A, Phan A, Perrier ND, Lee JE, Aloia T. Does Laparoscopic Adrenalectomy Jeopardize Oncologic Outcomes For Patients With Known Or Suspected Adrenocortical Carcinoma?. Society of American Gastrointestinal and Endoscopic Surgeons, 2013. e-Pub 2013.
Morris LF, Harris R, Milton DR, Waguespack SG, Habra MA, Jimenez C, Sellin RV, Lee JE, Perrier ND, Grubbs EG. Impact and Timing of Bilateral Adrenalectomy for Uncontrollable ACTH-Dependent Cushing’s Syndrome. American Association of Endocrine Surgery, 2013. e-Pub 2013.
Deniz F, Chuang H, Sircar K, Jimenez C, Wood CG, Rubin De Celis C, Habra MA. [18F]Fluorodeoxyglucose Positron Emission Tomography-Guided Therapy in Metastatic Adrenocortical Carcinoma: An Illustrative Case. Endocrine Society Meeting 2012, 2012. e-Pub 2012.
Samat A, Hamrahian AH, Elsayes KM, Remer EM, Rao P, Fergany A, Berber E, Habra MA. Clinical Characteristics of Adrenocortical Carcinomas Less Than 4 cm in Size: A Case Series. Endocrine Society Meeting 2012, 2012. e-Pub 2012.
Thosani S, Busaidy NL, Cabanillas M, Cote G, Grubbs E, Habra MA, Hu MI, Perrier N, Ayala-Ramirez M, Rich T, Waguespack S, Jimenez C. Characterization of Pheochromocytomas in MEN 2 with RET codon 918 and 634 mutations. Endocrine Society Meeting 2012, 2012. e-Pub 2012.
Busaidy NL, Megahed N, Hale K, Cabanillas M, Jimenez C, Habra MA, Kupferman M, Grubbs E, Mills G, Williams MD. Molecular Profiling of Advanced Thyroid Carcinomas. Endocrine Society 2012, 2012. e-Pub 2012.
Dadu R, Habra MA, Hu MI. Metastatic Papillary Thyroid Carcinoma to the Kidney — 30 Years after Initial Diagnosis. Endocrine Society 2012 meeting, 2012. e-Pub 2012.
Naing A, LoRusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan A, Habra MA, Kurzrock R. Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Metastatic Adrenocortical Carcinoma. J Clin Oncol 30(15):SUPPL; ABSTRACT NUMBER 4639, 2012. e-Pub 2012.
Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan AT, Waguespack S, Ayala-Ramirez M, Jimenez J, Sellin RV. The effect of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma: Retrospective cohort analysis. J Clin Oncol 30(15):Abstract 4641, 2012. e-Pub 2012.
Ayala-Ramirez M, Habra MA, Rich TA, Cote GJ, Busaidy NL, Anderson P, Waguespack SG, Phan A, Patel S, Jimenez C. Experience with the Tyrosine Kinase Inhibitor Sunitinib in Metastatic Pheochromocytomas and Paragangliomas. Endocrine Society Annual Meeting, Boston, MA(P2-633), 2011. e-Pub 2011.
Varghese JM, M Ayala-Ramirez M, Vaporciyan A, Liao Z, Habra MA, Jimenez C. Mediastinal Paraganglioma: The University of Texas MD Anderson Cancer Center (MDACC) Experience. Endocrine Society Annual meeting, Boston, MA(P2-636), 2011. e-Pub 2011.
Ayala-Ramirez M, Habra MA, Busaidy NL, Perrier ND, Rich TA, Waguespack SG, Phan A, Patel S, Jimenez C. Clinical Benefits of Chemotherapy in Patients with Metastatic Pheochromocytomas and Sympathetic Paragangliomas: Review of the Largest Single-Institution Experience. Endocrine Society Annual Meeting, Boston, MA(P2-627), 2011. e-Pub 2011.
Ayala-Ramirez M, Habra MA, Busaidy NB, Cote G, Rich T, Waguespack SG, Jimenez C. A catecholamine crisis on Mount Kilimanjaro: a hypoxia effect?. Endocrine Society 2010:Abstract # 851929, 2010. e-Pub 2010.
Ejaz S, Jamal S, Busaidy NL Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical Carcinoma: The University of Texas M.D Anderson Cancer Center Experience Update. American Society of Clinical Oncology 2010:Abstract # 54224, 2010. e-Pub 2010.
Barrera T, Rich TA, Perrier ND, McCutcheon IE, Jimenez C, Habra MA. Pheochromocytoma and Cushing's disease: A rare combination with unclear etiology. Endocrine Society 2010:(Abstract #852137), 2010. e-Pub 2010.
Ejaz S, Waguespack SG, Sellin RV, Busaidy NL, Jimenez C, Ying AK, Hu MI, Cabanillas ME, Gagel RF, Habra MA. ACTH-dependent Ectopic Cushing's Syndrome: The University of Texas M.D Anderson Cancer Center Experience. Endocrine Society 2010:(Abstract #851802), 2010. e-Pub 2010.
Ayala-Ramirez M, Hernandez M, Habra MA, Busaidy NB, Cote G, Rich T, Waguespack SG, Jimenez C. Clinical Risk Factors for Malignancy in Pheochromocytomas and Paragangliomas. Endocrine Society 2010:(Abstract # 851919), 2010. e-Pub 2010.
Khan MI, McCutcheon IE, Nogueras-González GM, Devin JK, Jimenez C, Habra MA, Levine NB, Waguespack SG. Post-operative day 3 cortisol as a predictor of HPA axis integrity after transsphenoidal surgery. Endocrine Society 2010:(Abstract#852602), 2010. e-Pub 2010.
Ayala-Ramirez M, Hernandez M, Habra MA, Busaidy NB, Cote G, Rich T, Waguespack SG, Jimenez C. Survival Rates in Patients with Metastatic Pheochromocytomas and Paragangliomas. Endocrine Society 2010:Abstract # 851929, 2010. e-Pub 2010.
Alford EM, Habra MA, Ying AK. Destructive Thyroiditis in Stem Cell Transplant Recipients. International Thyroid Congress 2010 ITC2010-1303, 2010. e-Pub 2010.
Ying AK, Jasim S, Waguespack SW, Rich TA, Grubbs EG, Jimenez C, Cote CG, Habra MA. Multiple Endocrine Neoplasia Type 2B with a RET Proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with RET M918T mutation. Multiple Endocrine Neoplasia Conference MEN2010,Gubbio, Italy. e-Pub 2010.
Shahani S, Fowler N, Routbor M, Habra MA. Primary thyroid plasmacytoma and potential rituximab induced plasmacytic differentiation of B-Cell lymphoma. American Association of Clinical Endocrinologists 18th meeting, 2009. e-Pub 2009.
Habra MA, Vassilopoulou-Sellin R. Contribution of routine chest x-ray in the long-term follow-up of patients with differentiated thyroid carcinoma - change, 2006. e-Pub 2006.
Picolos MK, Foringer JR, Habra MA, Couriel D, Sarlis NJ. Severe, Prolonged and Refractory Hypophosphatemia (HypoP) with High-dose Glucocorticoid (GC) Therapy. An Under-Recognized GC Induced Complication, 2005. e-Pub 2005.
Picolos MK, Habra MA, Safdar A, Sarlis NJ. Inactive Pulmonary Tuberculosis Can Mimic Metastasis from Papillary Thyroid Carcinoma in Diagnostic Radioiodine (131-I) Whole Body Scintigraphy (Dx RAI WBS), 2005. e-Pub 2005.
Habra MA, Thompson MA, Rodriguez MA, Routbort MJ, Holsinger FC, Perrier ND and Waguespack SG. Primary Natural Killer/ T Cell Lymphoma of the Adrenal Gland: A Unique Presentation of A Rare Disorder, 2005. e-Pub 2005.
Habra MA, Sellin R. Cervical Spine metastasis presenting as thyroid bed uptake in follicular thyroid Carcinoma, 2004. e-Pub 2004.
Busaidy NL, Habra MA, Jimenez C, Gagel RF. Diabetes Mellitus: A Possible Paraneoplastic Syndrome?, 2004. e-Pub 2004.
Habra MA, Jimenez C, Sellin RV. Cowden Syndrome Associated with Galactorrhea. Endocrine Practice, 2004. e-Pub 2004.
Busaidy, NL, Jimenez C, Habra MA, Gagel RF. Secondary or Tertiary Hyperparathyroidism in Tumor-Induced Osteomalacia. Endocrine Practice(10(suppl 1)):46, 2004. e-Pub 2004.
Busaidy N, Hymes SR, Jimenez C, Habra MA, Sarlis NJ. Progression of Medullary thyroid Carcinoma manifested as skin metastasis with inflammatory features, 2004. e-Pub 2004.
Jimenez C, Habra MA, Huang SC, Cote GJ, Evans DB, Shapiro S, El-Naggar AK, Gagel RF. Pheochromocytoma and Medullary Thyroid Carcinoma: A New Genotype-Phenotype Correlation of the RET Proto-Oncogene 891 Germline Mutation. Journal of Internal Medicine, 2004. e-Pub 2004.
Jimenez C, Habra MA, Busaidy N, Dekovitch A, Gagel RF, Sarlis NJ. Portal Hypertension: Yet another complication of Metastatic Medullary thyroid Carcinoma, 2004. e-Pub 2004.
Habra MA, Jimenez C, Morrison W, Keis MS, Sarlis NJ. Capcitabine and radiotherapy induce disease stabilization in a case of poorly differentiated follicular thyroid carcinoma, 2004. e-Pub 2004.
Hijazi RA, Habra MA, Sharma MD. Toxic multinodular goiter with extra-cardiac extension. Thyroid(13(7)):729, 2003. e-Pub 2003.
Hijazi RA, Habra MA, Picolos MK, Sellin RV. Occult sporadic Medullary thyroid carcinoma presenting with neck lymphadenopathy. Thyroid(13(7)):719, 2003. e-Pub 2003.
Busaidy NL, Jimenez C, et al HM. Two decades of experience with parathyroid carcinoma. Proc Am Soc Clin Oncol 22:516, 2003. e-Pub 2003.
Habra MA, Hijazi R, Marcelli M. Medullary thyroid carcinoma and Graves Disease, 2003. e-Pub 2003.
Salama B, Hamidi O, Wang TS, Sada A, Habra MA, Dogra P, Dackiw A, Oltmann S, Mirfakhraee S, Lingvay I, McKenzie T, Foster T, Lyden M, Dy B, Bancos. Postoperative adrenal insufficiency in patients with mild autonomous cortisol secretion. Endocrine Society 2025.
Habra MA, Chahla B, Bassett R, Hassan M, Varghese J. Association of Epidemiological and Risk Factors with Adrenocortical Carcinoma. Endocrine Society 2025.
Habra MA, Chen L, Balderrama-Brondani V, Marcal LP, Jimenez C, Varghese J, Shah AY, Campbell MT. Gemcitabine oxaliplatin combination in Patients with Advanced Adrenocortical Carcinoma. Endocrine Society 2025.
Habra MA, Villavicencio Torres CA, Yu K, Eid FW, Balderrama-Brondani V, Mahrokhian S, Vaidya A, Nekic AB, Kastelan D, Villares Fragoso MCB, Falhammar H, Ambroziak U, Bancos I. Evolution of Small (≤4 cm) Adrenal Lesions Diagnosed as Adrenocortical Carcinomas: A5 Multicenter Retrospective Cohort Study. European Congress of Endocrinology 2025.
Habra MA, Balderrama-Brondani V, Moussa MJ, Shah AY, Varghese J, Jimenez C, Campbell MT. Circulating tumor DNA analysis in adrenocortical carcinoma – A first retrospective cohort study. Endocrine Society 2025.
Habra MA, Hosseini H, Zhang M. Novel Targetable Biomarkers in Adrenocortical Carcinomas. The United States and Canadian Academy of Pathology’s 114th Annual Meeting.

Book Chapters

Habra MA, Balderrama-Brondani, V, Yaylaci, F, Chahla, Brenda. Adrenocortical carcinoma. In: Encyclopedia of Endocrine Disease. Elsevier, 2025.
Jimenez C, Armaiz-Pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, Habra MA. Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. In: Endocrine and Neuroendocrine Cancers. Cancers, 159-176, 2023.
Lee JE, Habra MA, Campbell MT. Malignant tumors of the adrenal gland. In: Holland-Frei Cancer Medicine. 10th. JohnWiley & Sons, Inc, 2023.
Habra MA, Else, T, Fassnacht, M. Adrenocortical Carcinoma. In: DeGroot’s Endocrinology: Basic Science and Clinical Practice. 8th. Elsevier, 2022.
Fisher ST, Asare EA, Habra MA, Perrier ND. Advances in the diagnosis and management of adrenocortical carcinoma. In: Advances in Treatment and Management in Surgical Endocrinology, 1st Edition. 1st. Elselvier, 2020.
Rothan SM, Habra MA, Elsayes KM. The incidental adrenal lesion. In: A practical and current approach for managing incidental findings. ARRS, 2019.
Romero MA, Habra MA, Perrier ND. Adrenal Tumors. In: UICC Manual of Clinical Oncology. 9th. John Wiley & Sons Limited, 2016.
Flores S, Habra MA. Thyroid Cancer Survivorship. In: Advances in Cancer Survivorship Management (MD Anderson Cancer Care Series). Springer, 2014.
Hu MI, Jimenez C, Busaidy NL, Habra MA. Long-Term and Late Endocrine Effects of Cancer Survivorship. In: Advances in Cancer Survivorship Management (MD Anderson Cancer Care Series). Springer, 2014.
Thomas RM, Habra MA, Perrier ND, Grubbs EG. Well-Differentiated Carcinoma of the Thyroid and Neoplasms of the Parathyroid Glands. In: The M.D. Anderson Surgical Oncology Handbook. 5th. Lippincott Willimans& Wilkins, 2012.
Haddad RY, Habra MA. Cancer of the Endocrine System. In: Cancer Principles & Practice of Oncology Review. 3rd. Lippinctot Williams & Wilkins, 2012.
Schultz PN, Stava CJ, Habra MA, Sellin RV. Adult Long-term Follow-up. In: M.D Anderson Manual of Medical Oncology. Second. McGraw Hill, 1341-1350, 2011.
Busaidy NL, Habra MA, Sellin RV. Endocrine Malignancies. In: M.D Anderson Manual of Medical Oncology. Second. McGraw Hill, 1039-1076, 2011.
Habra MA, Busaidy NL, Yeung J, Sellin RV. Endocrine and Metabolic Complications of Cancer Therapy. In: M.D Anderson Manual of Medical Oncology. Second. McGraw Hill, 1235-1255, 2011.
Haddad R, Habra MA. Cancer of Endocrine System. In: Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review. 2nd. WoltersKluwer/Lippincot Williams & Wilkins, 2009.
Habra MA, Vassilopoulou-Sellin R, Clayman G. Parathyroid Carcinoma. In: Advanced Therapy in Surgical Oncology. 1. B. C. Decker Incorporated, 2007.
Habra MA, Busaidy NL, Yeung SJ, Vassilopoulou-Sellin R. Endocrine Complications of Cancer Therapy. In: The MD Anderson Manual of Medical Oncology, 2006.
Busaidy NL, Habra MA, Vassilopoulou-Sellin R. Endocrine Malignancies. In: The MD Anderson Manual of Medical Oncology, 2006.
Amos KD, Habra MA, Perrier NC. Carcinoma of the Thyroid and Parathyroid Glands. In: The M.D. Anderson Surgical Oncology Handbook. 4th, 2006.
Habra MA. Chapter 21, In DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review. In: Endocrine Tumors. 1, 2005.

Books (edited and written)

Habra MA, Vassilopoulou-Sellin R. M.D. Anderson Atlas of Endocrine Neoplasia, 2006.

Less

CV information above last modified March 30, 2026

Mouhammed Amir Habra, M.D., F.A.C.P., F.A.C.E.

About Dr. Mouhammed Amir Habra

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Mouhammed Amir Habra, M.D., F.A.C.P., F.A.C.E.

About Dr. Mouhammed Amir Habra

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson